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Objectives The purpose of this study was to investigate whether a surrogate for renal neurohormonal activation, blood urea
nitrogen (BUN), could identify patients destined to experience adverse outcomes associated with the use of high-
dose loop diuretics (HDLD).
Background Loop diuretics are commonly used to control congestive symptoms in heart failure; however, these agents cause
neurohormonal activation and have been associated with worsened survival.
Methods Subjects in the BEST (Beta-Blocker Evaluation of Survival Trial) receiving loop diuretics at baseline were analyzed
(N  2,456). The primary outcome was the interaction between BUN- and HDLD-associated mortality.
Results In the overall cohort, HDLD use (160 mg/day) was associated with increased mortality (hazard ratio [HR]:
1.56; 95% confidence interval [CI]: 1.35 to 1.80). However, after extensively controlling for baseline characteris-
tics, this association did not persist (HR: 1.06; 95% CI: 0.89 to 1.25). In subjects with BUN levels above the me-
dian (21.0 mg/dl), both the unadjusted (HR: 1.59; 95% CI: 1.34 to 1.88) and adjusted (HR: 1.29; 95% CI: 1.07
to 1.60) risk of death was higher in the HDLD group. In patients with BUN levels below the median, there was no
associated risk with HDLD (HR: 0.99; 95% CI: 0.75 to 1.34) and after controlling for baseline characteristics, the
HDLD group had significantly improved survival (HR: 0.71; 95% CI: 0.49 to 0.96) (p interaction  0.018).
Conclusions The risk associated with HDLD use is strongly dependent on BUN concentrations with reduced survival in pa-
tients with an elevated BUN level and improved survival in patients with a normal BUN level. These data suggest
a role for neurohormonal activation in loop diuretic–associated mortality. (J Am Coll Cardiol 2011;58:375–82)
© 2011 by the American College of Cardiology Foundation
Published by Elsevier Inc. doi:10.1016/j.jacc.2011.01.052In the preceding decades, multiple therapies capable of
prolonging life have been developed for the treatment of
heart failure; however, loop diuretics have remained the
primary means to control congestive symptoms (1). Al-
See page 383
though effective in the maintenance of euvolemia, admin-
istration of loop diuretics can lead to significant neurohor-
monal activation (2,3). Given that the majority of therapeutic
advances in heart failure have centered on the concept of
neurohormonal antagonism, it is not surprising that there
From the *Department of Medicine, Cardiovascular Division, University of Pennsyl-
vania School of Medicine, Philadelphia, Pennsylvania; and the †Department of
Biostatistics and Epidemiology, University of Pennsylvania School of Medicine,
Philadelphia, Pennsylvania. This study was funded by National Institutes of Health
grant 5T32HL007843-15. The authors have reported that they have no relationships
to disclose.Manuscript received August 19, 2010; revised manuscript received December 2,
2010; accepted January 2, 2011.has been great interest regarding the influence of loop
diuretics on outcomes in patients with heart failure. Indeed,
numerous studies have reported a strong association be-
tween loop diuretics and worsened survival (4–9).
Providing further complexity to the relationship between
loop diuretics and adverse outcomes is the possibility that
elevated filling pressures directly contribute to negative
remodeling and heart failure progression (10–13). Two
recent studies have provided preliminary evidence to sup-
port the hypothesis that aggressive volume management is
associated with improved outcomes, even in the setting of
larger doses of loop diuretics (14,15). Thus, it is conceivable
that a given dose of loop diuretic could contribute to either
improved or worsened survival depending on the relative
benefit from decongestion versus the harm from neurohor-
monal activation. Because there is large interindividual vari-
ability in both heart failure phenotype and response to loop
diuretics, the threshold dose for toxic effects is likely specific to
each patient’s renal, cardiac, and neurohormonal physiology.
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BUN and Loop Diuretics July 19, 2011:375–82The clearance of blood urea ni-
trogen (BUN) is determined by
both the glomerular filtration rate
(GFR) and tubular reabsorption
of urea (16,17). Through both
direct and indirect mechanisms,
neurohormonal activation leads
to increased tubular urea reab-
sorption and decreases in the GFR
(16,18–20). Given that the detri-
mental cardiovascular effects of
loop diuretics are thought second-
ary to renally mediated neurohor-
monal activation and the fact that
tubular urea reabsorption parallels
the kidney’s neurohormonal status,
serum BUN may provide information related to the functional
neurohormonal impact of high-dose loop diuretics (HDLDs).
We hypothesized that if loop diuretics are causally related to
adverse outcomes via neurohormonal activation, loop diuretic–
associated mortality should be predominantly restricted to
patients with evidence of neurohormonal activation.
Methods
The BEST (Beta-Blocker Evaluation of Survival Trial) was
a National Heart, Lung, and Blood Institute (NHLBI)–
supported randomized, placebo-controlled trial investigat-
ing the impact of bucindolol, a nonselective beta-blocker, on
all-cause mortality in compensated chronic heart failure
patients. The design and primary results were previously
published (21). Briefly, 2,708 patients with New York Heart
Association (NYHA) functional class III or IV heart failure,
a left ventricular ejection fraction of 35%, and use of an
angiotensin-converting enzyme inhibitor for 1 month
(unless contraindicated) were randomized to bucindolol or
placebo. Exclusion criteria included reversible heart failure,
uncorrected primary valvular disease, decompensated heart
failure, life expectancy of 3 years, a serum creatinine level
of 3.0 mg/dl, or the use of a beta-blocker within 30 days
of baseline. The BEST was conducted and supported by the
NHLBI in collaboration with the BEST study investiga-
tors. This paper was prepared using a limited-access dataset
obtained from the NHLBI and does not necessarily reflect
the opinions or views of the BEST investigators or the
NHLBI.
All patients with a baseline loop diuretic dose of 10 mg
and a baseline BUN level were included in this analysis
(N  2,456). Total loop diuretic dose was converted to
urosemide equivalents (i.e., 1 mg bumetanide  20 mg
orsemide  40 mg furosemide). High-dose loop diuretic
use was defined, a priori, as a total daily dose of 160 mg
of furosemide equivalents, the dose corresponding to the
75th percentile in this cohort. The GFR was estimated
Abbreviations
and Acronyms
BUN  blood urea nitrogen
CI  confidence interval
GFR  glomerular filtration
rate
HDLD  high-dose loop
diuretic
HR  hazard ratio
IQR  interquartile range
NHLBI  National Heart,
Lung, and Blood Institute
NYHA  New York Heart
Associationusing the 4-variable Modification of Diet in Renal Disease qstudy equation (22). The analysis was based on baseline data
because that is the only time point with complete data
available in the BEST dataset. This study was approved by
our institutional review committee.
Statistical methods. Values reported are mean  SD,
edian (quartile 1 to quartile 3), and percentile. The
ndependent Student t test, Mann-Whitney U test, analysis
f variance, and the Kruskal-Wallis test were used to
ompare continuous parameters. Pearson’s chi-square was
sed to evaluate categorical variables. The primary outcome
f the study was all-cause mortality, and the primary
nalyses focused on the associations between HDLD use
nd mortality in subgroups stratified by a baseline BUN
evel above or below the median. Cox proportional model-
ng was used to evaluate time-to-event associations with
ll-cause mortality. To account for all potential confounders
vailable in this dataset, candidate covariates for multivari-
ble modeling were obtained by screening all baseline
ariables, and those with a univariate association with
ortality (p  0.2) in the population or stratum of interest
ere entered in the model. Covariates were removed using
ackward elimination (likelihood ratio), and variables with a
 0.2 were retained (23). Kaplan-Meier curves for death
f any cause were plotted for the 4 combinations of groups
etween BUN level above or below the median and HDLD
se. The x-axis was terminated when the remaining number
t risk was 10%. Stratum-specific hazard ratios (HRs)
ere derived from proportional hazards modeling of the
ndividual strata, and the significance of the interactions was
ormally assessed using models incorporating terms for the
ain effect of HDLD use, the main effect of the dichoto-
ous variable of interest, and the interaction between these
ariables. Cox regression analyses of loop diuretic dose
tratified by BUN level and their associated interaction
odels were subjected to 1,000 bootstrap replications (with
eplacement) to derive p values and 95% confidence inter-
als (CIs) for these analyses. Statistical analysis was per-
ormed with PASW Statistics, version 18.0 (SPSS Inc.,
hicago, Illinois) and significance defined as 2-tailed p 
.05.
esults
aseline characteristics and results of the overall BEST
opulation were previously reported (21). The primary
ndpoint of all-cause mortality did not show a statistically
ignificant difference between patients receiving bucindolol
r placebo. Baseline characteristics of subjects used in the
urrent analysis (those taking10 mg of loop diuretics with
baseline BUN level available) are presented in Table 1. In
otal, 27.7% of the population were taking HDLDs (total
aily dose 160 mg, n  680) at baseline, and of those
atients, 51.8% were taking 160 mg. In total, 33.3% of the
opulation died; the median follow-up was 721 days (inter-
uartile range [IQR]: 398 to 1,041 days).
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July 19, 2011:375–82 BUN and Loop DiureticsOverall, baseline indicators of heart failure disease sever-
ity were more common in patients taking HDLDs (Table 1).
Unadjusted, HDLDs were associated with significantly
increased incidence of all-cause mortality (HR: 1.56: 95%
CI: 1.35 to 1.80; p  0.0001). However, after controlling
or confounding variables (hemoglobin, GFR, BUN level,
erum sodium, serum uric acid, systolic blood pressure, left
entricular ejection fraction, Minnesota Living With Heart
ailure score, age, physical examination findings, baseline
edication use, history of diabetes, hypertension, and cor-
nary artery disease), the association between HDLD use
nd mortality was no longer significant (HR: 1.06; 95% CI:
.89 to 1.25; p  0.52).
Baseline BUN level was also strongly associated with
Baseline Characteristics of the Overall Cohort and Patients Takingor With a BUN Level Above Versus Be ow the Me ianTable 1 B s line Charact ristics of the Overall Cohor and Pator With a BUN Level Above Versus Below the Median
Characteristics
Overall Cohort
(N  2,456)
High-D
No
(n  1,776)
Demographics
Age, yrs 60.3 12.4 60.7 12.2
White race 68.7 70.8
Male 77.5 77.2
Medical history
Hypertension 59.8 57.5
Diabetes 36.9 33.0
Obstructive coronary artery disease 48.5 48.6
Physical examination
Heart rate, beats/min 82.5 13.4 81.6 13.1
Systolic blood pressure, mm Hg 118.1 19.5 119.8 19.6
Jugular venous distention 48.1 44.7
Peripheral edema 31.6 27.9
Rales 15.4 14.0
S3 gallop 45.9 42.3
Medications (baseline)
Digoxin 92.9 91.9
Vasodilators 44.7 41.4
ACE inhibitor 91.7 93.3
Bucindolol 50.1 48.5
Total loop diuretic dose, mg 80 (40–160) 160 (160–240)
Antiarrhythmic drug use 2.7 2.8
Laboratory values
Hemoglobin, g/dl 13.9 1.7 14.0 1.6
Serum sodium, mmol/l 138.9 3.4 139.2 3.2
Uric acid, mg/dl 8.3 2.4 7.9 2.2
Serum creatinine, mg/dl 1.3 0.4 1.2 0.4
GFR, ml/min/1.73 m2 64.6 22.6 66.2 22.4
BUN, mg/dl 21 (16–30) 20 (15–26)
Norepinephrine, pg/ml† 441 (305–642) 434 (298–616)
Functional status/ejection fraction
Ejection fraction, % 23 (17–29) 24 (18–30)
MLHF score 71.4 23.9 69.6 23.6
Values are mean  SD, %, or median (quartile 1 to quartile 3). Total loop diuretic dose expressed
iuretic defined as total daily dose of 160 mg of furosemide equivalents. Coronary artery diseas
ypass grafting. *Represents a significant p value. †Available in 1,922 subjects.
ACE  angiotensin-converting enzyme; BUN  blood urea nitrogen; GFR  glomerular filtrationncreased mortality (HR: 1.28 per 10-mg/dl increase; 95% aI: 1.24 to 1.33; p  0.0001), and patients with a BUN
evel above the median (21.0 mg/dl) had significantly
ncreased risk of death (HR: 2.30; 95% CI: 1.99 to 2.66;
 0.0001). Similar to HDLD status, a BUN level above
he median was associated with multiple markers of adverse
rognosis (Table 1). After controlling for confounding
ariables (loop diuretic dose, hemoglobin, GFR, serum
odium, serum uric acid, systolic blood pressure, left ven-
ricular ejection fraction, Minnesota Living With Heart
ailure score, age, physical examination findings, baseline
edication use, history of diabetes, hypertension, and cor-
nary artery disease), a BUN level above the median
emained significantly associated with worsened survival
HR: 1.30; 95% CI: 1.07 to 1.5; p  0.009). A BUN level
- Versus Low-Dose Loop DiureticsTaking High- Versus Low-Dose Loop Diuretics
op Diuretic BUN Level Above Median
Yes
 680) p Value
No
(n  1,236)
Yes
(n  1,220) p Value
2 12.7 0.006* 56.5 12.1 63.9 11.5 0.001*
63.2 0.001* 65.6 71.8 0.001*
78.4 0.529 73.7 81.3 0.001*
65.9 0.001* 57.3 62.3 0.011*
47.2 0.001* 29.3 44.5 0.001*
48.2 0.874 42.4 54.5 0.001*
8 13.9 0.001* 82.8 13.5 82.2 13.4 0.241
6 18.4 0.001* 121.1 19.4 115.2 19.0 0.001*
57.0 0.001* 43.9 52.2 0.001*
41.4 0.001* 27.6 35.5 0.001*
18.9 0.003* 12.6 18.1 0.001*
55.6 0.001* 42.9 48.9 0.003*
95.3 0.004* 92.7 93.0 0.745
53.4 0.001* 39.5 49.8 0.001*
87.5 0.001* 92.6 90.8 0.097
54.3 0.010* 48.8 51.4 0.197
(40–80) 0.001* 80 (40–120) 80 (60–160) 0.001*
2.6 0.879 2.1 3.3 0.071
7 1.7 0.001* 14.2 1.5 13.7 1.8 0.001*
2 3.7 0.001* 139.2 3.1 138.6 3.6 0.001*
4 2.7 0.001* 7.4 2.0 9.1 2.5 0.001*
4 0.5 0.001* 1.0 0.2 1.5 0.4 0.001*
4 22.6 0.001* 76.9 20.1 52.5 17.8 0.001*
(18–40) 0.001* 16 (13–18) 30 (24–41) 0.001*
(315–687) 0.007* 404 (283–567) 494 (328–703) 0.001*
(16–27) 0.001* 24 (18–30) 22 (17–28) 0.001*
1 23.9 0.001* 71.7 23.7 71.1 24.1 0.543
emide equivalents (1 mg bumetanide  20 mg torsemide  40 mg furosemide). High-dose loop
ed as a 70% stenosis on angiography or history of percutaneous intervention or coronary artery
LHF  Minnesota Living With Heart Failure.Highients
ose Lo
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BUN and Loop Diuretics July 19, 2011:375–82use (odds ratio: 2.1, p  0.0001). Regardless of HDLD
iuretic status, an elevated BUN level was associated with
ncreased mortality; however, in patients taking HDLDs,
n elevated BUN level (HR: 3.09; 95% CI: 2.31 to 4.14;
 0.0001) had significantly greater risk than patients not
aking HDLDs (HR: 1.94; 95% CI: 1.63 to 2.30; p 
.0001).
In analyses stratified by BUN level, patients with BUN
evels above the median continued to have a highly signif-
cant increase in mortality associated with HDLD use
ersus low-dose loop diuretic use (HR: 1.59; 95% CI: 1.34
o 1.88; p  0.0001) (n events  537) (Fig. 1). Character-
stics of the 4 patient groups presented in Figure 1 can be
found in Table 2. In patients with a BUN level below the
median, however, the univariate association between mor-
tality and HDLD use was no longer present (HR: 0.99; 95%
CI: 0.75 to 1.34; p  0.99) (n events  282, p interaction 
0.008) (Fig. 1). Controlling for confounding variables (se-
rum sodium, GFR, serum uric acid, hemoglobin, systolic
blood pressure, left ventricular ejection fraction, Minnesota
Living With Heart Failure score, age, medication use,
physical examination findings, history of diabetes, hyper-
tension, and coronary artery disease), the association be-
tween HDLD use and mortality remained significant (HR:
1.29; 95% CI: 1.07 to 1.60; p  0.012) in patients with a
BUN level above the median. However, after controlling for
confounding variables in patients with a BUN level below
Figure 1 Unadjusted Survival Plots
Grouped by BUN Level and HDLD Use
Kaplan-Meier plots for total survival grouped by serum blood urea nitrogen
(BUN) and high-dose loop diuretic (HDLD) use. High and low BUN levels repre-
sent values above and below the median, respectively.the median (GFR, serum uric acid, hemoglobin, systolic
blood pressure, left ventricular ejection fraction, Minnesota
Living With Heart Failure score, age, baseline medication
use, physical examination findings, sex, history of diabetes,
hypertension, and coronary artery disease), a significant
inverse association between mortality and HDLD use
emerged (HR: 0.71; 95% CI: 0.49 to 0.96; p  0.042). The
adjusted interaction term remained significant (p  0.018)
(Fig. 2). Coefficients for all variables in the final interaction
model can be found in Online Table 1. Similar analyses
stratified by volume overload, physical examination findings,
or alternative variables associated with mortality did not
yield any significant differences in HRs, and all interaction
terms were nonsignificant (Table 3). We were unable to
detect any interaction effect on HDLD-associated mor-
tality with respect to race (p interaction  0.353) or sex
(p interaction  0.807).
Despite these noted differences in mortality, left ventric-
ular ejection fraction (p  0.43), Minnesota Living With
Heart Failure score (p  0.74), jugular venous distention
(p  0.10), edema (p  0.07), pulmonary rales (p  0.26),
presence of S3 gallop (p  0.24), and baseline medication
use (p  0.17 for all medications) were similar in patients
taking HDLDs, regardless of whether BUN levels were
above or below the median. Moreover, median loop diuretic
doses were also similar (160 mg [IQR: 160 to 240 mg] for
both groups; p  0.63). Supporting the concept of neuro-
hormonal activation, patients taking HDLDs had signifi-
cantly higher plasma norepinephrine levels (available in
81%) if baseline BUN levels were above the median com-
pared with those with BUN levels below the median (491
pg/ml [IQR: 324 to 725 pg/ml] vs. 422 pg/ml (IQR: 286 to
644 pg/ml; p  0.005). Similarly, in patients taking
HDLDs, serum uric acid was higher (10.0  2.8 mg/dl vs.
8.3  2.1 mg/dl, p  0.0001) and serum sodium was lower
(138 3.9 mEq/l vs. 139 3.3 mEq/l, p 0.007) in those
with BUN levels above the median.
Discussion
The principal finding of this study is the strong interaction
between serum BUN level and the mortality risk associated
with HDLD use. In the overall population, HDLD use had
a significant unadjusted association with worsened survival;
however, after extensively controlling for baseline con-
founders, this association was no longer present. Most
importantly, in patients with a BUN level above the median,
the use of HDLDs was associated with significantly in-
creased mortality, an association that persisted after control-
ling for baseline characteristics. In contrast, patients with a
BUN level below the median had a significant association
between HDLD diuretic use and improved survival in
multivariable analysis. These results suggest that serum
BUN, a variable that parallels neurohormonal activation in
the kidney, may identify patient populations that are at risk
379JACC Vol. 58, No. 4, 2011 Testani et al.
July 19, 2011:375–82 BUN and Loop Diureticsof experiencing adverse neurohormonal effects from
HDLDs.
In the kidney, the macula densa serves a key role in the
regulation of renin secretion via the monitoring of tubular
sodium chloride content (24). Sodium chloride entry into
these cells is facilitated by the sodium/potassium/2-chloride
cotransporter, the primary target of loop diuretics. As a
result, loop diuretic administration leads to increased renin
release and the neurohormonal cascade that follows (24–26).
This loop diuretic–induced neurohormonal activation has
been documented both acutely and chronically in humans,
and loop diuretics have been associated with adverse out-
comes in a number of studies (2–9). Additionally, in
experimentally induced heart failure, administration of loop
Baseline Characteristics of the 4 CombinationsAbove or Below he Median and High- Versus LoTable 2 B seline Charact rist cs of the 4 CAbove or Below the Median and Hig
Characteristics
Low
Low BUN Level
(n  972)
Demographics
Age, yrs 57.0 12.2
White race 67.7
Male 73.4
Medical history
Hypertension 44.8
Diabetes 72.9
Obstructive coronary artery disease 42.9
Physical examination
Heart rate, beats/min 82.0 13.4
Systolic blood pressure, mm Hg 122.3 19.8
Jugular venous distention 41.6
Peripheral edema 25.3
Rales 11.5
S3 gallop 40.4
Medications (baseline)
Digoxin 91.7
Vasodilators 36.5
ACE inhibitor 94.0
Bucindolol 47.9
Total loop diuretic dose, mg 40 (40–80)
Antiarrhythmic drug use 2.1
Laboratory values
Hemoglobin, g/dl 14.2 1.5
Serum sodium, mmol/l 139.4 3.0
Uric acid, mg/dl 7.2 1.9
Serum creatinine, mg/dl 1.0 0.2
GFR, ml/min/1.73 m2 76.7 20.1
BUN, mg/dl 15 (13–18)
Norepinephrine, pg/ml* 401 (282–552)
Functional status/ejection fraction
Left ventricular ejection fraction, % 24 (19–30)
MLHF score 70.7 23.7
Values are mean  SD, %, or median (quartile 1 to quartile 3). Total lo
20 mg torsemide 40 mg furosemide). High-dose loop diuretic define
disease defined as a 70% stenosis on angiography or history of per
between-group differences with an uncorrected p value0.001 with th
and digoxin use (p  0.20). *Available in 1,922 subjects.
Abbreviations as in Table 1.diuretics leads to a more rapid progression of left ventriculardysfunction (27). However, the multiple redundant feed-
back loops governing renal blood flow, GFR, and renal
neurohormonal status makes the response to any given dose
of loop diuretic a highly individualized phenomenon
(28,29). This was illustrated in a study in which the same
dose of loop diuretic was given to a group of heart failure
patients (29). Interestingly, plasma renin activity and aldo-
sterone concentration increased in some subjects yet de-
creased in others. Moreover, neither hormonal change
correlated with the volume of diuresis, which varied more
than 20-fold among subjects.
Much like creatinine, urea is freely filtered through the
glomerulus. However, urea undergoes substantial tubular
reabsorption (24). This tubular reabsorption of urea is
oups Between BUN Levelse Loop Diuretic Usenations of G oups B tween BUN Level
rsus Low-Dose Loop Diuretic Use
ose High Loop Dose
igh BUN Level
(n  804)
Low BUN Level
(n  248)
High BUN Level
(n  432)
65.2 10.6 54.9 11.5 61.6 12.7
74.6 57.3 66.70
81.8 75.0 80.30
39.8 34.7 33.80
59.8 62.1 47.50
55.5 40.3 52.80
81.0 12.8 86.0 13.6 84.414.1
116.8 18.9 116.0 17.2 112.2 18.9
48.4 52.8 59.30
31.0 36.8 44.00
17.0 16.6 20.10
44.5 52.6 57.30
92.3 96.8 94.40
47.3 51.2 54.60
92.4 87.1 87.70
49.1 52.0 55.60
80 (40–80) 160 (160–240) 160 (160–240)
3.6 2.4 2.80
13.7 1.7 14.0 1.6 13.5 1.8
139.0 3.3 138.6 3.3 137.9 3.9
8.6 2.2 8.2 2.1 10.0 2.8
1.4 0.4 1.1 0.2 1.6 0.4
53.6 18.0 77.7 20.1 50.4 17.3
28 (24–37) 16 (14–19) 34 (27–51)
94 (330–696) 422 (286–644) 491(324–725)
23 (17–28) 21 (16–27) 21 (16–26)
68.1 23.4 75.7 23.2 76.4 24.4
retic dose expressed as furosemide equivalents (1 mg bumetanide 
tal daily dose of160 mg of furosemide equivalents. Coronary artery
ous intervention or coronary artery bypass grafting. All variables had
sion of antiarrhythmic drug use (p 0.25), bucindolol use (p 0.55),of Grw-Doombi
h- Ve
Loop D
H
4
op diu
d as to
cutane
e excluhighly dependent on neurohormonal activation through
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BUN and Loop Diuretics July 19, 2011:375–82both direct effects on the distal nephron and indirect effects
of decreased renal blood flow and increased proximal tubular
solute and water reabsorption (16,18–20). Given that loop
diuretic–induced neurohormonal activation is primarily a
renally mediated process, it is biologically plausible that a
renal marker of neurohormonal activation, such as clearance
of BUN, would parallel the adverse effects of loop diuretics.
Patients with more severe degrees of heart failure gener-
ally receive larger doses of loop diuretics and logically
confounding by indication has been suggested to account for
the association between loop diuretic dose and mortality
(30). The strong, qualitative interaction between BUN, a
surrogate for neurohormonal activation, and the effect of
loop diuretics on outcomes argues against confounding by
indication as the sole mechanism behind these observations.
The possibility that confounding by indication is only
operative in high-risk individuals, potentially explaining the
previously noted interaction, also appears to be unlikely
given that there were no significant interactions when the
cohort was dichotomized into high- and low-risk groups
with numerous other variables. Moreover, the finding that a
protective effect of HDLDs was found in patients without
Figure 2 Adjusted Survival Plots
Grouped by BUN and HDLD Use
Survival plots for total survival grouped by serum blood urea nitrogen (BUN)
and high-dose loop diuretic (HDLD) use after adjustment for potential confound-
ers. Survival plots are adjusted for hemoglobin, serum creatinine, BUN, serum
sodium, serum uric acid, systolic blood pressure, left ventricular ejection frac-
tion, Minnesota Living With Heart Failure score, age, physical examination find-
ings, baseline medication use, history of diabetes, hypertension, and coronary
artery disease.elevated BUN levels also provides evidence against con-founding by indication as the primary mechanism linking
loop diuretics and mortality.
If these data are replicated, formal clinical investigation
may be warranted to evaluate volume management strate-
gies based on serum BUN concentrations or other more
direct markers of renal neurohormonal activation. Addi-
tionally, novel methods of decongestion such as intermittent
ultrafiltration or the use of natriuretic doses of potassium-
sparing diuretics may allow both minimization of loop
diuretic doses and the maintenance of euvolemia. The
development of more reliable methods of intravascular
volume assessment may also provide an improved risk/
benefit ratio for loop diuretics by avoiding occult hypervol-
emia and hypovolemia.
Study limitations. Given the post-hoc nature of this study,
the limitations of retrospective analyses apply. Uncontrolled
confounding cannot be excluded. Although the inclusion of
patients with a serum creatinine level as high as 3.0 mg/dl
was permitted in the trial, the median creatinine value was
1.2 mg/dl, with approximately 80% of patients having a
creatinine level1.5 mg/dl. As a result, these findings likely
do not apply to a population with more advanced intrinsic
renal insufficiency because the reduced glomerular filtration
of urea may overwhelm neurohormone-related urea clear-
ance in determining serum BUN levels. In addition to the
rate of clearance, urea production can be influenced by
factors such as protein catabolism and diet, introducing
additional noise and potential bias into the assessment of
neurohormonal activation with BUN. Additionally, treating
physicians were not blinded to the serum BUN concentra-
tions and may have modified treatment based on these
values. BUN levels are probably not static over time, and
serial data points might yield further information and
address additional hypotheses. The analysis of norepineph-
rine levels was limited by missing values in approximately
19% of the study population. The BEST required a NYHA
functional class of III or IV for enrollment, and thus these
results may not be applicable to populations with less severe
heart failure symptoms. Unlike the other large-scale beta-
blocker clinical trials, bucindolol was not found to have a
statistically significant impact on all-cause mortality. Al-
though this may have been secondary to a lack of efficacy of
bucindolol, it is also possible the BEST patient population
was somehow different from other beta-blocker trial popu-
lations, making it important to validate our findings in
additional cohorts.
Conclusions
The association between high doses of loop diuretics and
increased mortality in this study was largely dependent on
the presence of an elevated BUN level, a surrogate for
neurohormonal activation. In patients with elevated BUN
levels, higher mortality was noted with the use of HDLDs.
However, in patients with lower serum BUN levels, HDLD
nt p va
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data suggest that the worsened survival associated with loop
diuretics may be mediated by neurohormonal activation.
Further research is necessary to validate these findings and
investigate diuretic dosing strategies that can both minimize
neurohormonal activation and maintain optimal volume
control.
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